BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Employees - 5, CEO - Mr. Anthony Amato, Sector - Healthcare, Country - US, Market Cap - 19.97M

Altman ZScore(max is 10): -467.24, Piotroski Score(max is 10): 4, Working Capital: $-1920000, Total Assets: $842000, Retained Earnings: $-255345000, EBIT: -11514000, Total Liabilities: $2264000, Revenue: $40000

AryaFin Target Price - $-0.01 - Current Price $0.82 - Analyst Target Price $2.50